(Q44670935)

English

Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Alzheimer's disease

0 references

0 references

vascular dementia

1 reference

based on heuristic

inferred from title

author name string

A F Kurz

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

T Erkinjuntti

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

G W Small

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

S Lilienfeld

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

C R Venkata Damaraju

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

European Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

633-640

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00677.X

21 January 2018

Identifiers

10.1046/J.1468-1331.2003.00677.X

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44670935&oldid=2031278511"